Cancer Biology Program

癌症生物学项目

• 批准号: 10627030
• 负责人: Resham Bhattacharya
• 金额: $ 5.07万
• 依托单位: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-05-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10627030
• 关键词: Adipose tissue; Advanced Malignant Neoplasm; Affect; Apoptosis; Area; Attention; BMI1 gene; Basic Science; Cachexia; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Research Project; Catchment Area; Cell Cycle; Chemoresistance; Clinical Trials; Collaborations; Colon; Community Outreach; Diagnosis; Direct Costs; Doctor of Philosophy; ERBB2 gene; Epithelial Cells; Event; Evolution; Fostering; Funding; Goals; Growth Factor; Institution; Investigation; Journals; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Mammary Neoplasms; Mediating; Molecular; Muscular Atrophy; Mutation; Neoplasm Metastasis; Normal Cell; Obesity; Oklahoma; Oncogenes; Oncogenic; Peer Review; Publications; Publishing; Reporting; Research; Research Peer Review; Role; Science; Serous; Signal Pathway; Signal Transduction; Signaling Molecule; Therapeutic; Training; Translating; Tumor Suppressor Genes; angiogenesis; cancer cell; cancer drug resistance; cancer initiation; cancer prevention; cancer therapy; cell growth; cell stroma; community engagement; insight; interest; malignant breast neoplasm; meetings; member; microbiome; neoplastic cell; pre-clinical; programs; resistance mechanism; stem-like cell; translational cancer research; tumor; tumor microenvironment; tumor progression

CANCER BIOLOGY PROGRAM: ABSTRACT The overall goal of the Cancer Biology (CB) program at the Stephenson Cancer Center (SCC) is to foster research in basic mechanisms that define normal and neoplastic cell growth to gain new insights into cancer prevention, diagnosis and treatment. CB is a new program in this CCSG application, representing an evolution of the previous Preclinical Translational Cancer Research (PTCR) program driven by a strategic reorganization of programmatic research at the SCC. Research is organized around three integrated aims that focus on 1) cancer cell signaling pathways, 2) tumor microenvironment and 3) mechanisms of chemoresistance. Specific attention is placed on conducting basic mechanisms research related to Community Outreach and Engagement (COE)-identified priority cancers that affect Oklahoma (the SCC catchment area). Program members bring a diverse range of transdisciplinary expertise in basic cancer mechanisms, including: the functions of oncogenes and tumor suppressor genes; regulators of cell cycle and apoptosis; regulators of angiogenesis and metastasis; and aberrant signaling that leads to chemoresistance. The CB program seeks to channel these transdisciplinary interests in a collaborative, team-based approach. Focused interactions for members have helped foster collaboration and advance CB research. During the reporting period, the CB program conducted 135 interactive activities, including meetings, seminars, and training events. The CB program is led by Min Li, PhD and Resham Bhattacharya, PhD, who have complementary expertise in investigating basic mechanisms of cancer (Li) and translating discoveries into clinical trials (Bhattacharya). In 2021, the CB program had 39 total members (23 full, 16 associate), representing 11 different academic departments. Total peer-reviewed research funding was $6.38M, of which $2.15M was from NCI (annual, direct cost). More than a third (34%) of total peer-reviewed funding was from NCI, highlighting the cancer focus of this basic science-oriented program. Total research funding was $7.29M, with 58 active cancer-focused projects. CB members published 439 articles in peer-reviewed journals over the past five years. Of these, 24% were intra-programmatic and an exceptional 41% were inter-programmatic, underscoring the high degree of collaboration, both within the program and with members in the SCC’s Cancer Therapeutics (CT) and Cancer Prevention and Control (CPC) programs. Multi-institutional publications (n=297) account for 68% of the total. The number and percentage of high-impact publications increased over the period, from 12 (14%) in 2017 to 24 (24%) in 2021, averaging 18% for the period. This significant increase in high-impact publications highlights the quality of science being conducted by CB members.

癌症生物学项目：摘要 斯蒂芬森癌症中心 (SCC) 癌症生物学 (CB) 项目的总体目标是培养 研究定义正常和肿瘤细胞生长的基本机制，以获得对癌症的新见解 预防、诊断和治疗。 CB 是 CCSG 应用程序中的一个新程序，代表了一种演变 先前由战略重组驱动的临床前转化癌症研究 (PTCR) 计划 SCC 的规划研究。研究围绕三个综合目标进行组织，重点关注 1) 癌细胞信号通路、2) 肿瘤微环境和 3) 化疗耐药机制。具体的 重点开展社区外展相关基础机制研究 Engagement (COE) 确定了影响俄克拉荷马州（SCC 集水区）的优先癌症。程序 成员带来了基本癌症机制方面的各种跨学科专业知识，包括： 癌基因和抑癌基因的功能；细胞周期和细胞凋亡的调节剂；的监管者 血管生成和转移；以及导致化疗耐药的异常信号传导。 CB 计划旨在 以协作、团队为基础的方法引导这些跨学科的兴趣。重点互动 成员帮助促进合作和推进 CB 研究。报告期内，CB 计划开展了 135 场互动活动，包括会议、研讨会和培训活动。 CB 该项目由 Min Li 博士和 Resham Bhattacharya 博士领导，他们在以下领域拥有互补的专业知识 研究癌症的基本机制 (Li) 并将发现转化为临床试验 (Bhattacharya)。 2021 年，CB 计划共有 39 名成员（23 名正式成员，16 名准成员），代表 11 个不同的学术领域 部门。同行评审研究经费总额为 638 万美元，其中 215 万美元来自 NCI（年度、 直接成本）。同行评审资金总额中超过三分之一 (34%) 来自 NCI，凸显了对癌症的关注 这个以科学为导向的基础计划。研究经费总额为 729 万美元，其中 58 项活跃于癌症领域 项目。过去五年，CB 成员在同行评审期刊上发表了 439 篇文章。其中，24% 是计划内的，特别是 41% 是计划间的，强调了高度的 项目内部以及与 SCC 癌症治疗 (CT) 和癌症成员的合作 预防和控制 (CPC) 计划。多机构出版物（n=297）占总数的68%。 在此期间，高影响力出版物的数量和比例有所增加，从 2017 年的 12 种 (14%) 增加到 2021 年为 24 (24%)，同期平均为 18%。高影响力出版物的显着增加凸显了 CB 成员进行的科学质量。